NCCN Guidelines®: Treatment recommendations and response monitoring

Bosutinib (BOSULIF®) is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a treatment option for patients with CML in need of 2nd- or later-line TKI therapy1,a
Pfizer Statement: There are no data demonstrating efficacy or safety for bosutinib in second line following dasatinib or nilotinib.

 

NCCN Guidelines® includes BOSULIF as a treatment recommendation for multiple mutations1

Reference
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.1.2018. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed August 8, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way.

NCCN Guidelines® for Chronic Myeloid Leukemia (CML)

The National Comprehensive Cancer Network® (NCCN®) recommends monitoring response during treatment. Monitoring with quantitative polymerase chain reaction (QPCR) using IS every 3 months is recommended for all patients after initiating therapy, including those who meet response milestones at 3, 6, and 12 months, and beyond. After BCR-ABL1 0.1%-1% (IS) has been achieved, molecular monitoring is recommended every 3 months for 2 years and every 3 to 6 months thereafter.1
The following monitoring guidelines provide important information on monitoring the response to TKI therapy in patients with chronic phase (CP) CML.1

For more CML monitoring guidance, please reference the full NCCN Clinical Practice Guidelines in Oncology for Chronic Myeloid Leukemia V.1.2018.


Reference
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.1.2018. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed August 8, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way.